1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
|
2 |
任 丽, 邹明远, 朱行春, 等. 姜黄素通过Keap1-Nrf2通路抑制甲状腺乳头状癌B-CPAP细胞的增殖、迁移及侵袭[J]. 南方医科大学学报, 2023, 43(8): 1356-62.
|
3 |
Mao JX, Zhang QH, Zhang HY, et al. Risk factors for lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis[J]. Front Endocrinol, 2020, 11: 265. DOI: 10.3389/fendo.2020.00265
|
4 |
Dotinga M, Vriens D, van Velden FHP, et al. Reinducing radioiodine-sensitivity in radioiodine-refractory thyroid cancer using lenvatinib (RESET): study protocol for a single-center, open label phase II trial[J]. Diagnostics: Basel, 2022, 12(12): 3154. DOI: 10.3390/diagnostics12123154
|
5 |
Zhang XW, Xiong H, Duan JL, et al. The prognostic significance of the BIN1 and CCND2 gene in adult patients with acute myeloid leukemia[J]. Indian J Hematol Blood Transfus, 2022, 38(3): 481-91. DOI: 10.1007/s12288-021-01479-w
|
6 |
Conway JW, Braden J, Wilmott JS, et al. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy[J]. Front Immunol, 2022, 13: 1030147. DOI: 10.3389/fimmu.2022.1030147
|
7 |
Zhong L, Li YS, Xiong L, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives[J]. Signal Transduct Target Ther, 2021, 6: 201. DOI: 10.1038/s41392-021-00572-w
|
8 |
Li X, Fang J, Wei G, et al. CircMMP9 accelerates the progression of hepatocellular carcinoma through the miR-149/CCND2 axis[J]. J Gastrointest Oncol, 2022, 13(4): 1875-88. DOI: 10.21037/jgo-22-677
|
9 |
Wang D, Zhang Y, Che YQ. CCND2 mRNA expression is correlated with R-CHOP treatment efficacy and prognosis in patients with ABC-DLBCL[J]. Front Oncol, 2020, 10: 1180. DOI: 10.3389/fonc.2020.01180
|
10 |
Yue Q, Xu Y, Deng X, et al. Circ-PITX1 promotes the progression of non-small cell lung cancer through regulating the miR-1248/CCND2 axis[J]. Onco Targets Ther, 2021, 14: 1807-19. DOI: 10.2147/ott.s286820
|
11 |
Richardson TE, Walker JM. CCND2 amplification is an independent adverse prognostic factor in IDH-mutant lower-grade astrocytoma[J]. Clin Neuropathol, 2021, 40(4): 209-14. DOI: 10.5414/np301354
|
12 |
Dai W, Shi Y, Hu W, et al. Long noncoding RNA FAM225B facilitates proliferation and metastasis of nasopharyngeal carcinoma cells by regulating miR-613/CCND2 axis[J]. Bosn J Basic Med Sci, 2022, 22(1): 77-86.
|
13 |
Chen N, Yin D, Lun B, et al. LncRNA GAS8-AS1 suppresses papillary thyroid carcinoma cell growth through the miR-135b-5p/CCND2 axis[J]. Biosci Rep, 2019, 39(1): BSR20181440. DOI: 10.1042/bsr20181440
|
14 |
Leone V, D’Angelo D, Rubio I, et al. MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1α[J]. J Clin Endocrinol Metab, 2011, 96(9): E1388-98. DOI: 10.1210/jc.2011-0345
|
15 |
Yuan S, Liu Z, Yu S, et al. CCND2 and miR-206 as potential biomarkers in the clinical diagnosis of thyroid carcinoma by fine-needle aspiration cytology[J]. World J Surg Oncol, 2023, 21(1): 22. DOI: 10.1186/s12957-023-02899-w
|
16 |
Abbott M, Ustoyev Y. Cancer and the immune system: the history and background of immunotherapy[J]. Semin Oncol Nurs, 2019, 35(5): 150923. DOI: 10.1016/j.soncn.2019.08.002
|
17 |
Kołat D, Kałuzińska Ż, Bednarek AK, et al. Determination of WWOX function in modulating cellular pathways activated by AP-2α and AP-2γ transcription factors in bladder cancer[J]. Cells, 2022, 11(9): 1382. DOI: 10.3390/cells11091382
|
18 |
Varricchi G, Loffredo S, Marone G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20(16): E3934. DOI: 10.3390/ijms20163934
|
19 |
Zhang J, Gao J, Cui J, et al. Tumor-associated macrophages in tumor progression and the role of traditional Chinese medicine in regulating TAMs to enhance antitumor effects[J]. Front Immunol, 2022, 13: 1026898. DOI: 10.3389/fimmu.2022.1026898
|
20 |
Morana O, Wood W, Gregory CD. The apoptosis paradox in cancer[J]. Int J Mol Sci, 2022, 23(3): 1328. DOI: 10.3390/ijms23031328
|